Cardiovascular diseases remain the leading cause of death worldwide, accounting for nearly 20 million deaths each year. Rapid ...

FREMONT, Calif., Feb. 24, 2025 /PRNewswire/ — Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announce the release of the ...

Interest in biomarkers has exploded in recent years, driven by improvements in data collection and analysis, burgeoning interest in personalized medicine, and efforts to increase the success rate for ...

Recent research is helping to expand the potential biomarker landscape in non–small cell lung cancer (NSCLC) and may soon ...

A new wave of automated, inexpensive, and high-throughput multiplexing technologies has been widely reported on of late. Diagnostic laboratories and clinical pharmacologists will find these ...

The SPEAR UltraDetect™ pTau231 biomarker assay kit is designed for Alzheimer’s disease research using plasma samples. It must be used in combination with the SPEAR UltraDetect™ Reaction Kit and is ...

The SPEAR UltraDetect ™ GFAP Biomarker Assay Kit is a wash-free, ultra-precise diagnostic method for testing glial fibrillary acidic protein (GFAP) and is suitable for neurotrauma and central nervous ...

Please provide your email address to receive an email when new articles are posted on . The in vitro immunoassay is being developed by Roche in partnership with Eli Lilly & Co. Blood-based biomarker ...

Glial fibrillary acidic protein (GFAP), a blood biomarker, can be used to rapidly distinguish between hemorrhagic and ischemic stroke, according to a new prospective study. The hope, researchers say, ...

NeuroTherapia has concluded its Phase IIa clinical trial of NTRX-07, an orally available molecule, for Alzheimer's disease ...